| 🚨 THE OPENING THESISWhile you were watching META crater -7.96% and NVDA bleed -4.16%, a completely different story was writing itself in biotech. KOD at $39.76 exploded +74.77% on 13M volume. OLPX at $2.01 rocketed +51.13% on 104M shares traded. This wasn't random. While tech got slaughtered by China's DeepSeek AI fears, money rotated into biotech plays with actual FDA catalysts and real revenue visibility. The smart money moved while everyone else panicked about artificial intelligence competition. 📊 TAPE RECAPFRIDAY'S BLOODBATH BY THE NUMBERS Nasdaq:-2.38% to 21,408 S&P 500:-1.74% to 6,477 VIX:+8.42% to 29.75 Oil:+2.71% to $97.04 |
TRADE SIGNAL: Biotech names with FDA catalysts in Q2 are setting up for momentum continuation. Look for volume confirmation above yesterday's breakouts. |
KOD surges 75% on breakthrough eye drug approval  |
|
| | | | | | The 2026 pipeline looks very different from years past. | It's rare for IPOs to arrive with this kind of scale: | ~$1.5 trillion target valuation
$20+ billion in annual revenue
55% year-over-year growth
$1.4+ billion in pre-tax profit
240+ million monthly users
8 consecutive years of profitability | These aren't 10-year projections — they're current figures tied to private companies preparing for public markets. | Access the full report FREE. |
| |
| | |
| 💥 THE MOVERSOLPX rebounds 51% as beauty sector finds its footing  |
Kodiak Sciences (KOD) became Friday's hero with its massive +74.77% surge to $39.76 on breakthrough eye drug approval news. The ophthalmology play traded 13.2M shares - nearly 10x normal volume. This is what happens when biotech meets real FDA validation while tech faces existential AI threats. Olaplex Holdings (OLPX) bounced hard +51.13% to $2.01 on massive 104M volume as beauty stocks found buyers after weeks of selling. The hair care play showed classic oversold reversal patterns that sharp traders spotted early. TRADE SIGNAL: Watch for continuation in KOD above $35 support. OLPX needs volume follow-through above $1.80 to confirm the reversal. |
But the real story was the divergence. While EEIQ exploded +209.15% on 112M volume and VSA rocketed +140.35% on 115M shares, the Magnificent 7 got demolished. META -7.96%, NVDA -4.16%, GOOGL -3.44% all bled as China's DeepSeek spooked AI investors. 🎯 THE ONE THAT GOT AWAYEpicQuest Education (EEIQ) at $8.44 delivered the day's biggest move with a staggering +209.15% surge on 112M volume. The education tech play caught fire on AI learning platform news just as traditional AI stocks collapsed. Classic sector rotation in real-time. THE MISS THAT STINGS EEIQ:+209.15% on 112M volume VSA:+140.35% on 115M volume FCHL:+107.60% on 46M volume |
TRADE SIGNAL: Small-cap momentum plays over 100M volume often see follow-through Monday. Watch for pre-market gaps and early volume confirmation. |
|
| | ⚡ TODAY'S SETUPMonday opens with clear sector rotation signals. Oil at $97.04 keeps energy plays in focus while biotech momentum from Friday's breakouts sets up for continuation trades. The VIX +8.42% spike creates oversold bounces in beaten-down names. Watch pre-market volume in Friday's leaders. KOD needs to hold $35 support for the eye drug story to maintain credibility. OLPX faces the $1.80 test where real buyers separate from momentum chasers. TRADE SIGNAL: Biotech breakouts with FDA catalysts + small-cap momentum plays over 50M volume. Avoid mega-cap tech until DeepSeek fears clear. |
📈 THE CLOSEFriday's session exposed the new market reality: AI dominance is over, sector rotation is king. While everyone obsessed over Chinese AI competition, the real money moved into biotech approvals and energy plays. KOD +74.77%, OLPX +51.13%, oil +2.71% - that's where the alpha lived. Monday morning will tell us if this rotation has legs or was just a one-day anomaly. But when 100M+ volume flows into forgotten names while the giants bleed, smart traders pay attention. See you at the open.
— Cal Torres, The Trading Desk P.S. While everyone's chasing the obvious biotech plays, I've been digging into a completely different angle that could dwarf these eye drug gains. There's a medical technology shift happening right now that's flying under the radar, but the early movers are already positioning for what could be the biggest healthcare disruption since telemedicine exploded.
Learn more here → |
|
| Your interaction with our content, in any format, is appreciated. We value your time and the trust you place in our communications. Thank you for being an active member of our community, and we look forward to continued exchanges in the future. Privacy Policy Wall Street Watchdogs ("the Company") values the privacy of visitors to Wall Street Watchdogs site and users of our services. This notice explains how we collect, use, and protect information. Why You're Receiving This Email You're receiving this email because at some point, you opted in to receive updates, news, or information on a specific topic we've previously discussed or shared. Whether it was through a subscription, a form submission, or another form of communication, your information was shared willingly, and we respect your decision to connect with us. Thank you for taking the time to read this email. This message is part of an ongoing conversation between us, and I want to take a moment to ensure you have full transparency about why you received this message, how your information is handled, and what to expect from future emails. If you're wondering about the nature of our correspondence, rest assured that we aim to keep all emails relevant, timely, and from unnecessary clutter. This includes respecting your inbox and refraining from sending irrelevant messages. A Commitment to Non-Intrusive Emails We aim to create a non-intrusive communication experience. This means we won't overwhelm your inbox with excessive messages, and we work hard to ensure our content remains clear and concise. The purpose of this email is to stay connected with you and provide updates or information that we believe is meaningful. If we ever fail to meet these standards, we encourage you to let us know. Feedback, whether positive or constructive, is always appreciated. Your thoughts help us understand how we can do better and improve our communication approach. While we cannot promise every suggestion will be implemented, we will take the time to carefully review and consider your input. Accessibility and Communication If you have any trouble accessing the unsubscribe page, managing preferences, or understanding why you're receiving this email, you can reach out directly to our support team. We aim to provide a response within a reasonable time frame and address your concerns effectively. Our communication is designed to be as inclusive as possible, but we know there's always room for improvement. If you have any feedback on how we can make our emails more accessible or relevant, please don't hesitate to share. Your Privacy is Important We value your trust and take your privacy very seriously. The information you provide is securely stored and never shared, sold, or used outside the purpose for which you provided it. This privacy policy describes how we collects, uses, and protects your information. We collect information you voluntarily provide, such as your name, email address, or phone number. We may also collect technical data from your visit, including browser type, operating system, and your IP address. We use this information to respond to your inquiries, provide access to services, and improve our communications. We do not share your information with unrelated third parties. Some of our services may use third-party tools that store or process data on our behalf. These tools are selected with care and are expected to maintain data responsibly. We do not knowingly collect personal information from children under 13 years of age. If we discover that such information was provided without parental consent, we will delete it promptly. You can request to update or delete your personal information by contacting us. We may update this privacy policy occasionally. Changes will be reflected on the page. Orders with Wall Street Watchdogs are handled using secure processes. If there is a need to update delivery details, someone from our team may contact you. Please note, we do not ask for personal payment information by email. You can enable extra sign-in protection and use strong security to help keep you safe. We regularly review our systems and follow best practices to help protect your information. If you notice anything unusual, it may be helpful to review your settings. Transparency is our priority, and we're happy to address any questions you might have. How to Unsubscribe or Manage Your Preferences We understand that everyone's inbox is different. If you ever find our emails no longer relevant, there's no hard feelings. You can easily manage your email preferences or unsubscribe using the link provided below. By clicking the unsubscribe link, you'll be taken to a page where you can either adjust your communication preferences (such as receiving fewer emails or only on specific topics) or completely remove yourself from our list. The process is straightforward, and any changes will take effect promptly. We don't use tricks or gimmicks to keep you subscribed. Our priority is to ensure that our emails add value to your day, and if they don't, we respect your decision to part ways. Legal Information We comply with all applicable laws and regulations regarding email communication. This includes adhering to laws and maintaining the highest standards for consent-based communication. Your trust matters, and we work diligently to ensure every email you receive meets these requirements. If you need further clarification on our compliance policies or legal obligations, please ask. Transparency and accountability are central to our communication strategy, and we're happy to provide additional details if needed. Contact Information We strive to ensure all communication channels are open and readily available to you. Whether it's a question, comment, or concern, our team is ready to assist. For assistance, please contact our team via email by replying to this email. A Final Note Emails are one of the many ways we stay connected, but we understand they aren't perfect for everyone. If there's another way you'd prefer to communicate or stay updated, let us know. Whether it's through social media, a direct call, or another channel, we're open to finding the most effective way to share information with you. We want to emphasize that our goal is never to disrupt or clutter your inbox. Every email sent is intended to provide value, and we genuinely appreciate your time and attention. This footer was designed to ensure transparency, provide essential information, and give you full control over your communication preferences. We hope it meets your expectations, but if there's anything you'd like to see improved, we're always here to listen. Best regards, Wall Street Watchdogs |
|
Tidak ada komentar:
Posting Komentar